Amolimogene + Amolimogene
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Cervical Dysplasia
Conditions
Uterine Cervical Dysplasia
Trial Timeline
Jul 1, 2005 → May 1, 2009
NCT ID
NCT00264732About Amolimogene + Amolimogene
Amolimogene + Amolimogene is a phase 2/3 stage product being developed by Eisai for Uterine Cervical Dysplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00264732. Target conditions include Uterine Cervical Dysplasia.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00264732 | Phase 2/3 | Completed |
Competing Products
20 competing products in Uterine Cervical Dysplasia